Interferon-beta-1b-induced short-and long-term signatures of treatment activity in multiple sclerosis

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 443-451

  Croze, E ^a,b   Yamaguchi, K D ^c   Knappertz, V ^d   Reder, A T ^e   Salamon, H ^c  

^a Global Biologics Research   (United States)

^b International Review of Investigational Science   (United States)

^c Knowledge Synthesis   (United States)

^d BAYER CORPORATION   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

biomarker signatures; IKK epsilon; interferon 1b; multiple sclerosis; NRF2; oxidative stress

Indexed keywords

BETA INTERFERON; FATTY ACID; GLATIRAMER; INTERFERON BETA SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR OLA1; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; ENERGY METABOLISM; EXPANDED DISABILITY STATUS SCALE; FATTY ACID METABOLISM; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; KNOWLEDGE BASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; ND6 GENE; OPTIC NERVE DISEASE; PLEIOTROPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIOXIDANTS; BIOMARKERS, PHARMACOLOGICAL; DOWN-REGULATION; FATTY ACIDS; FEMALE; GTP-BINDING PROTEINS; HUMANS; I-KAPPA B KINASE; INTERFERON-BETA; MALE; MIDDLE AGED; MITOCHONDRIA; MULTIPLE SCLEROSIS; NADH DEHYDROGENASE; NF-E2-RELATED FACTOR 2; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84884587008     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.27     Document Type: Article

References (55)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204: 208-231.
2. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann of Neurol 2009; 65: 239-248.
3. Markowitz CE. The current landscape and unmet needs in multiple sclerosis. Am J Managed Care 2010; 16(Suppl 8): S211-S218.
4. Wagner JA. Innovations driving biomarker evaluation and use. Biomarkers Med 2010; 4: 779-781.
5. Micheel C. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (Micheel C, Ball J (eds)), National Acad Press, 1 September 2010.
6. Croze E. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J IFN Cyto Res 2010; 30: 743-749.
7. Vandenbroeck K, Urcelay E, Comabella M. IFN-beta pharmacogenomics in multiple sclerosis. Pharmacogenomics 2010; 11: 1137-1148.
8. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-264.
9. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. The type I interferon receptor: structure, function, and evolution of a family business. J IFN Cyto Res 1999; 19: 1069-1098.
10. Gok B, Okutan O, Beskonakli E, Palaoglu S, Erdamar H, Sargon MF. Effect of immunomodulation with human interferon-beta on early functional recovery from experimental spinal cord injury. Spine 2007; 32: 873-880.
11. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010; 74(Suppl 1): S17-S24.
12. Agrawal SM, Yong VW. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007; 79: 99-126.
13. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BGW et al. Interferon b-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011; 76: 1222-1228.
14. Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, Reder AT et al. IFNbeta-regulated genes show abnormal expression in therapy-naive relapsingremitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 2008; 195: 116-120.
15. Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J et al. IFNbeta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J IFN Cyto Res 2008; 28: 317-331.
16. Croze E, Knappertz V, Yamaguchi KD, Reder A, Salamon H. Integration of molecular mechanism studies and biological knowledge-bases reveals the presence of a possible neuronal preservation process linked to mitochondrial dysfunction and oxidative stress in IFNB-1b-treated MS patients. Multiple Sclerosis 2010; 16(Suppl 5) (abstract P565).
17. Croze E, Knappertz V, Yamaguchi KD, Reder AT, Salamon H. Long-term interferon beta treatment in MS patients elevates brain-specific carnitine palmitoyltransferase, a key regulator of mitochondrial fatty acid oxidation. Multiple Sclerosis 2010; 16(Suppl 5) (abstract P884).
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
19. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
21. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11: 147-161.
22. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
23. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 2011; 39: 685-690.
24. R Development Core Team. A Language and Environment for Statistical Computing: R Foundation for Statistical Computing. Vienna, Austria, 2010.
25. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004; 20: 93-99.
26. Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008; 274: 48-53.
27. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinogenesis 2009; 48: 91-104.
28. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P et al. Fumeric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf antioxidant pathway. Brain 2011; 134: 678-692.
29. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR et al. The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann NY Acad Sci 2008; 1147: 61-69.
30. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julia E et al. A type I interferon signature in monocytes is associated with poor response to interferonbeta in multiple sclerosis. Brain 2009; 132: 3353-3365.
31. van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, Killestein J et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PloS One 2008; 3: e1927.
32. Vosslamber S, van Baarsen LGM, Verweij CL. Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics 2009; 10: 97-108.
33. Reder AT. MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology 2010; 75: 1222-1223.
34. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinicoradiographic paradox in the BEYOND trial. Multiple Sclerosis 2011; 18: 181-195.
35. Arnason BG, Dayal A, Qu ZX, Jensen MA, Genç K, Reder AT. Mechanisms of action of interferon-beta in multiple sclerosis. Sem Immunopath 1996; 18: 125-148.
36. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009; 8: 1111-1119.
37. International Multiple Sclerosis Genetics Conssortium (IMSGC). IL12A, MPHOSPH9/ CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immunity 2010; 11: 397-405.
38. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002; 129: 205-215.
39. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 2010; 1802: 66-79.
40. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571.
41. Sørensen PS, Jønsson A, Mathiesen HK, Blinkenberg M, Andresen J, Hanson LG et al. The relationship between MRI and PET changes and cognitive disturbances in MS. J Neurol Sci 2006; 245: 99-102.
42. Guzmán M, Blázquez C. Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins, Leukot Essent Fatty Acids 2004; 70: 287-292.
43. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS et al. Crosssectional study assessing long-term safety of interferon-beta-1b for relapsingremitting MS. Neurology 2010; 74: 1877-1885.
44. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929.
45. Gonzalo R, Garcia-Arumi E, Llige D, Marti R, Solano A, Montoya J et al. Free radicals-mediated damage in transmitochondrial cells harboring the T14487C mutation in the ND6 gene of mtDNA. FEBS Lett 2005; 579: 6909-6913.
46. Fauser S, Leo-Kottler B, Besch D, Luberichs J. Confirmation of the 14568 mutation in the mitochondrial ND6 gene as causative in Leber's hereditary optic neuropathy. Ophthalmic Genet 2002; 23: 191-197.
47. Kovács GG, Höftberger R, Majté nyi K, Horváth R, Barsi P, Komoly S et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005; 128: 35-41.
48. Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I et al. Molecular cloning and characterization of two novel retinoic acid-inducible orphan Gprotein-coupled receptors (GPRC5B and GPRC5C). Genomics 2000; 67: 8-18.
49. Zhang J, Rubio V, Lieberman MW, Shi ZZ. OLA1, an Obg-like ATPase, suppresses antioxidant response via nontranscriptional mechanisms. Proc Natl Acad Sci USA 2009; 106: 15356-15361.
50. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PloS One 2011; 6: e16172.
51. Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM et al. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009; 138: 961-975.
52. Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis 2009; 68: 257-263.
53. Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007; 315: 1274-1278.
54. Hiscott J. Another detour on the Toll road to the interferon antiviral response. Nature 2004; 11: 1028-1030.
55. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsingremitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010; 70: 1545-1577.